Velsera's Innovative Tumor Profiling Technology Receives Approval

Transforming Cancer Diagnostics through Innovation

Velsera, a prominent player in healthcare technology, is thrilled to announce a significant milestone in cancer diagnostics. The company’s advanced tumor profiling technology plays a crucial role in the Illumina TruSight™ Oncology Comprehensive in vitro diagnostic (IVD) results report. By merging its extensive knowledge base with tumor profiling expertise, Velsera enhances patient care and paves the way for personalized treatment across the nation.

Partnership with Illumina

The collaboration between Velsera and Illumina was born out of a shared commitment to advance cancer diagnostics and improve access to targeted therapeutics. Since it began in late 2018, this partnership has evolved into a vital alliance for the healthcare community. Velsera's Knowledge Base (KB) is essential in the TSO Comprehensive test, streamlining the adoption of next-generation sequencing (NGS)-based diagnostics for laboratories.

Impact on Cancer Treatment

According to Nicki Berry, Head of Region-Americas at Illumina, the collaboration has been instrumental in delivering the Vision for the TruSight™ Oncology Comprehensive test. This NGS-based test simplifies the identification of key cancer biomarkers, promoting better clinical decisions.

Enhancing Patient Outcomes

Velsera's Knowledge Base content plays a vital role in determining the clinical significance of cancer mutations. This advancement leads to personalized and effective treatment plans tailored to individual patient needs. Jamie Littlejohns, CEO of Velsera, emphasizes the company's commitment to making targeted therapeutics accessible to healthcare systems and patients worldwide. The latest achievement highlights their drive to translate research discoveries into significant improvements in patient outcomes.

Advancing Precision Medicine

As precision medicine continues to evolve, Velsera is positioned as a leader, collaborating with industry giants like Illumina to reshape the diagnostics landscape. This commitment aims to accelerate the market entry of IVD solutions, setting new standards for sequencing technologies and ensuring faster and more accurate biomarker identification, which greatly enhances patient care.

About Velsera

Founded in 2023 from the merger of Seven Bridges, PierianDx, and UgenTec, Velsera is on a mission to be the go-to platform for discovery, evidence generation, and clinical delivery in precision medicine. The company operates in key regions including Europe and Asia, helping professionals make informed decisions about delivering the right therapy at the right time to patients.

Contact Information

For inquiries, please contact:

Brian Lassiter
Manager, Commercial Marketing
Velsera
(857) 357-3060 | ext 3060

Frequently Asked Questions

What is Velsera's role in cancer diagnostics?

Velsera provides advanced tumor profiling technology that enhances the Illumina TruSight Oncology Comprehensive IVD, integrating data for improved patient treatment.

How does the partnership with Illumina affect cancer treatment?

The partnership allows for the development of an NGS-based test that simplifies the identification of important cancer biomarkers, ultimately leading to better clinical outcomes.

What is the impact of Velsera's Knowledge Base?

Velsera's Knowledge Base aids in classifying cancer mutations, helping clinicians create personalized treatment plans based on the clinical significance of these mutations.

What advances has Velsera made in precision medicine?

Velsera has positioned itself as a leader in precision medicine by accelerating the development and accessibility of innovative diagnostic solutions for cancer care.

How can I contact Velsera for more information?

You can reach Brian Lassiter, Manager of Commercial Marketing, at (857) 357-3060 for inquiries about Velsera's services and offerings.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.